Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options

Autosomal dominant polycystic kidney disease (ADPKD) is the reported etiology in 10% of end-stage kidney disease (ESKD) patients and has an estimated prevalence of 12.5 million cases worldwide across all ethnicities. There have been major advancements over the last two decades in understanding the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Yeshwanter, Duriseti, Parikshit, Chebib, Fouad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Nephrology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346401/
https://www.ncbi.nlm.nih.gov/pubmed/35354242
http://dx.doi.org/10.23876/j.krcp.21.309
_version_ 1784761642953736192
author Radhakrishnan, Yeshwanter
Duriseti, Parikshit
Chebib, Fouad T.
author_facet Radhakrishnan, Yeshwanter
Duriseti, Parikshit
Chebib, Fouad T.
author_sort Radhakrishnan, Yeshwanter
collection PubMed
description Autosomal dominant polycystic kidney disease (ADPKD) is the reported etiology in 10% of end-stage kidney disease (ESKD) patients and has an estimated prevalence of 12.5 million cases worldwide across all ethnicities. There have been major advancements over the last two decades in understanding the pathogenesis and development of disease-modifying treatment options for ADPKD, culminating in regulatory approval of tolvaptan for ADPKD patients at risk of rapid progression to kidney failure. This review highlights the genetic mutations associated with ADPKD, defines patients at risk of rapid progression to ESKD, and focuses on the management of ADPKD in the era of disease-modifying agents.
format Online
Article
Text
id pubmed-9346401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Nephrology
record_format MEDLINE/PubMed
spelling pubmed-93464012022-08-04 Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options Radhakrishnan, Yeshwanter Duriseti, Parikshit Chebib, Fouad T. Kidney Res Clin Pract Review Article Autosomal dominant polycystic kidney disease (ADPKD) is the reported etiology in 10% of end-stage kidney disease (ESKD) patients and has an estimated prevalence of 12.5 million cases worldwide across all ethnicities. There have been major advancements over the last two decades in understanding the pathogenesis and development of disease-modifying treatment options for ADPKD, culminating in regulatory approval of tolvaptan for ADPKD patients at risk of rapid progression to kidney failure. This review highlights the genetic mutations associated with ADPKD, defines patients at risk of rapid progression to ESKD, and focuses on the management of ADPKD in the era of disease-modifying agents. The Korean Society of Nephrology 2022-07 2022-03-29 /pmc/articles/PMC9346401/ /pubmed/35354242 http://dx.doi.org/10.23876/j.krcp.21.309 Text en Copyright © 2022 The Korean Society of Nephrology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial and No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) which permits unrestricted non-commercial use, distribution of the material without any modifications, and reproduction in any medium, provided the original works properly cited.
spellingShingle Review Article
Radhakrishnan, Yeshwanter
Duriseti, Parikshit
Chebib, Fouad T.
Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title_full Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title_fullStr Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title_full_unstemmed Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title_short Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
title_sort management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346401/
https://www.ncbi.nlm.nih.gov/pubmed/35354242
http://dx.doi.org/10.23876/j.krcp.21.309
work_keys_str_mv AT radhakrishnanyeshwanter managementofautosomaldominantpolycystickidneydiseaseintheeraofdiseasemodifyingtreatmentoptions
AT durisetiparikshit managementofautosomaldominantpolycystickidneydiseaseintheeraofdiseasemodifyingtreatmentoptions
AT chebibfouadt managementofautosomaldominantpolycystickidneydiseaseintheeraofdiseasemodifyingtreatmentoptions

Ejemplares similares